Introduction
Major depressive disorder (MDD) affects more than 300 million people worldwide1,2 and is projected to become the leading cause of disability by 20303. Among the variety of pharmacological and psychotherapeutic treatments available, cognitive behavioral therapy (CBT) is often recommended as a first-line treatment for MDD4–6. This well-established intervention teaches patients to identify and modify thoughts and behaviors to reduce maladaptive patterns and enhance mood and well-being7. CBT is an effective treatment option8–10 with enduring effects11. Nevertheless, while CBT is comparable in effectiveness to pharmacotherapy, up to 50% of patients with MDD fail to achieve remission following CBT or achieve only partial response12. Due to the heterogeneity of depression, there is no current method to determine if CBT is likely to benefit a given individual. As a result, some patients may end up spending months in a therapy that will not alleviate their depressive symptoms. Moreover, access to publicly-funded CBT is limited in many countries, and certified cognitive-behavioral therapists are scarce, hampering access to this therapy13–17. To reduce the time spent in ineffective therapy and optimize resource allocation within health systems, it is essential to identify which patients are likely to benefit from this therapy.
Recently, electroencephalography (EEG) was used to identify biomarkers that can predict the response to pharmacological and brain stimulation treatments18–23. In this regard, previous research has investigated the predictive utility of several resting-state EEG measures, such as band power, cordance (a measure of band power normalized in both spatial and frequency dimensions) or asymmetry (a measure derived from calculating the ratio between band power in left and right hemispheres).
Early studies identified an association between lower baseline delta power and response to tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants, imipramine and paroxetine, respectively24,25. In contrast, a recent study found greater baseline delta oscillations to be predictive of improvement in loss of insight following treatment with several SSRIs and the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine23. An increase in delta activity after a few weeks of SSRI treatments is likewise associated with treatment response21,26. An increase in slow oscillation (including delta) was also observed following electroconvulsive therapy (ECT) but results were not specific to responders to the treatment20,27,28.
The link between theta activity and response to antidepressants is mixed. Baseline theta power was lower in responders to a tricyclic (imipramine), several SSRIs, and an SNRI (venlafaxine)24,29. On the other hand, greater baseline theta power was found in responders to another tricyclic (nortriptyline), several SSRIs, and rTMS22,30–33. Responders to the SSRI paroxetine, and combined treatment with the SSRI escitalopram and bupropion (a norepinephrine/dopamine-reuptake inhibitor (NRI)) exhibited an early increase in theta power26,34. However, early reduction in theta cordance was also observed in responders to venlafaxine, fluoxetine (SSRI), and bupropion35–41. Theta cordance has also been shown to both reduce and increase in responders to rTMS after 1 week of treatment37,42. These inconsistencies across studies could be explained by distinct treatment mechanisms but could also be due to differences in age ranges, and differences in rTMS treatment protocols (10 Hz left-dorsolateral prefrontal cortex rTMS in the Bares study, versus 1 Hz right-dorsolateral prefrontal cortex rTMS in the Hunter study).
A number of authors have reported an association between increased baseline alpha oscillations and response to different antidepressant medication types (including fluoxetine, tricyclics imipramine and amitriptyline, and combined treatment with escitalopram and bupropion) in addition to rTMS treatment24,34,43–47. A reduction in alpha power after several weeks of treatment has also been reported in responders to several SSRIs21,26,34. Similarly, a decrease in activity at high frequencies (including alpha) was observed following ECT treatment20,28. Some studies have also probed the predictive utility of alpha asymmetry to antidepressant treatments, although these results are inconsistent21,34,43–46,48. One study also investigated alpha asymmetry as a potential biomarker of response to CBT, but this was done in the context of anxiety, and not depression49. It is also interesting to note that some studies found evidence of greater left hemisphere advantage for verbal dichotic listening in responders than non-responders to CBT50–52. However, these studies did not used EEG measures and it is unclear if the findings are related specifically to asymmetry in the alpha band.
Finally, findings in other frequency bands have been scarce: a trend for greater beta power in responders to imipramine and paroxetine was reported in early studies24,25; and an increase in gamma connectivity after 1 week of treatment was observed in responders to rTMS33.
Despite some promising results, so far as we are aware no study to date has investigated the predictive utility of resting EEG measures prior to CBT for depression. Identifying biomarkers that can help predict the response to this widely used psychotherapy may assist in the development of more effective personalized treatments. Based on previous results, greater alpha power at baseline and reduction in the alpha activity in responders appear to be a common finding across other treatment modalities and could be a general marker of response to antidepressant treatment, including CBT. However, findings in other frequency bands could be more treatment specific. In this regard, one mechanism specific to CBT may involve changes in cognitive control53–57. For example, an alteration in neural correlates of inhibitory control following therapy has been reported in a recent study56. Considering that low-frequency oscillations have been associated with cognitive control in previous literature58–67, delta and theta activity could also be expected to be markers of response to CBT.
Here, we sought to assess whether spectral features derived from resting-state EEG could be used to classify responders and non-responders to CBT. In a study by the Canadian Biomarker Integration Network for Depression (CAN-BIND), adults with MDD were recruited to undergo 16 weeks of CBT. Resting-state EEG signals were recorded for each participant at baseline (week 0), week 2 of therapy, and following completion of the therapy course (week 16). Here, EEG data at baseline was used to identify potential biomarkers of response to CBT. We also used data at week 2 to investigate whether early changes in EEG oscillatory activity would help predicting response to the therapy. A participant was categorized as a responder if the reduction in their Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to post-treatment therapy was equal to or more than 50%, and as a non-responder, if the reduction was less than 50%. We hypothesized that power spectral EEG measures would differ between subsequent responders and non-responders in exhibiting greater alpha power at baseline and an early reduction in alpha activity. We also speculated that response to CBT would be associated with lower delta and theta power at baseline and an early increase in delta and theta activity.
CC BY 4.0. "Resting-state EEG delta and alpha power predict response to cognitive behavioral therapy in depression: a Canadian biomarker integration network for depression study" by Schwartzmann B, Quilty LC, Dhami P et al., Scientific reports (2023). https://doi.org/10.1038/s41598-023-35179-4. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Peer-reviewed and open access; full text from PubMed Central (PMC10209049). Headings and layout adapted for reading; figures and tables are in the original.